Patents Assigned to Behringwerke Aktiengesellschaft
  • Patent number: 8552159
    Abstract: Provided herein are carbohydrate complement-modified bifunctional glycoproteins, and their use in tumor-selective therapy. The bifunctional glycoproteins comprise a first component that specifically binds to a tumor-specific antigen and a second component having enzymatic activity by means of which a non-toxic prodrug is cleaved into a cytotoxic drug. The carbohydrate complement comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, N-acetyllactose, glucose and fucose. The modified carbohydrate complement contributes to increased relative concentration of the glycoproteins at the site of the tumor, and enhanced clearance from the general circulation and non-tumor sites.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: October 8, 2013
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Klaus Bosslet, Joerg Czech, Dieter Hoffmann
  • Publication number: 20040202646
    Abstract: Provided herein are carbohydrate complement-modified bifunctional glycoproteins, and their use in tumor-selective therapy. The bifunctional glycoproteins comprise a first component that specifically binds to a tumor-specific antigen and a second component having enzymatic activity by means of which a non-toxic prodrug is cleaved into a cytotoxic drug. The carbohydrate complement comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, N-acetyllactose, glucose and fucose. The modified carbohydrate complement contributes to increased relative concentration of the glycoproteins at the site of the tumor, and enhanced clearance from the general circulation and non-tumor sites.
    Type: Application
    Filed: April 2, 2004
    Publication date: October 14, 2004
    Applicant: Behringwerke Aktiengesellschaft
    Inventors: Klaus Bosslet, Joerg Czech, Dieter Hoffmann
  • Publication number: 20030073126
    Abstract: The invention relates to a method for the detection of an analyte in a competitive immunoassay in the presence of an analyte derivative and first and second receptor molecules, and to a kit for carrying out this detection method.
    Type: Application
    Filed: July 17, 1997
    Publication date: April 17, 2003
    Applicant: Behringwerke Aktiengesellschaft
    Inventors: STEPHAN DR. NEUENHOFER, HEINZ-JURGEN DR. SKRZIPCZYK, PETER DR MOIZ, REINHARD KASMARKER
  • Publication number: 20020068329
    Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
    Type: Application
    Filed: December 12, 1997
    Publication date: June 6, 2002
    Applicant: Behringwerke Aktiengesellschaft
    Inventors: MATHIAS GEHRMANN, GERHARD SEEMANN, KLAUS BOSSLET, JORG CZECH
  • Patent number: 6162631
    Abstract: A novel immunodeficiency virus is disclosed which has the designation MVP-2901/94 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 95012601. The characteristic antigens which can be obtained from the virus and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the partial DNA and amino acid sequences of the virus.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: December 19, 2000
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hans-Peter Hauser, Stefan Knapp, Stefan Brust, Lutz G. Gurtler, Josef Eberle, Lazare Kaptue, Leopold Achengui Zekeng
  • Patent number: 6020461
    Abstract: A nucleotide sequence characteristic of Neisseria gonorrhoeae is disclosed. The sequence can be the basis for hybridization type, nucleic acid-based, rapid, in vitro diagnostic assays. The unique nature of the sequence makes it possible to clearly discriminate N. gonorrhoeae from other Neisseria species thus eliminating or substantially reducing the number of false positive readings. A 350 base pair N. gonorrhoeae DNA restriction fragment was cloned after subtractive hybridization to Neisseria meningitidis DNA. In further cloning experiments the sequences adjacent to the original 350 base pair fragment were determined. A portion of this sequence was shown to detect 105 of 106 N. gonorrhoeae strains and no other Neisseria species. In addition to use as detection probes, all or portions of the nucleotide sequence can be used as a ligand for the sandwich capture of N. gonorrhoeae sequences and as primers for in vitro amplification of N. gonorrhoeae sequences.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: February 1, 2000
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Charles Garrett Miyada, Teresa L. Born
  • Patent number: 5981697
    Abstract: The present invention is directed to the generation of antibodies which preferentially bind to fibrinogen fragments E1, E2, and E3, but exhibit little or no cross-reactivity against fibrin monomer and fibrinogen. Thus, the invention provides synthetic peptides containing defined amino acid sequences corresponding to the carboxy terminal regions of the E fragments which arise as a result of plasmin cleavage of fibrin and fibrinogen. The synthetic peptides may be synthesized chemically, or through genetic manipulations, and may contain additional amino acid sequences which are not contiguous with the defined E fragment sequences.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: November 9, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Michael Kraus, Werner Stuber
  • Patent number: 5955100
    Abstract: Glycosyl-spacer-drugs compounds (prodrugs), their preparation and their use as pharmaceuticals are described.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: September 21, 1999
    Assignees: Behringwerke Aktiengesellschaft, Laboratories Hoechst S/A
    Inventors: Klaus Bosslet, Jorg Czech, Dieter Hoffmann, Cenek Kolar, Fran.cedilla.ois Tillequin, Jean-Claude Florent, Michel Azoulay, Claude Monneret, Jean-Claude Jacquesy, Jean-Pierre Gesson, Michel Koch
  • Patent number: 5939389
    Abstract: The use of C1-inactivator for the production of a pharmaceutical for the prophylaxis and treatment of capillary leak syndrome (generalized extravasation) and circulator shock (refractory hypotension) in severe burns or scalds, in polytrauma, in operations under conditions of extracorporeal circulation, in the use of cytokines, endogenous mediators, and mediator hybrids and growth factors produced by genetic engineering, or capillary leak syndrome and veno-occlusive disease of the liver in therapeutically or prophylactically indicated bone marrow transplantation is described.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: August 17, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernd Eisele, Ulrich Delvos, Andreas Jessel
  • Patent number: 5902740
    Abstract: The invention relates to a process for the decontamination of cell cultures containing mycoplasmas. In this process the cell cultures infected by mycoplasmas undergo an antibiotic treatment in a first step, and cells still infected are then eliminated by 6-methylpurine deoxyriboside solution in a second step.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: May 11, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Klaus-Dieter Langner
  • Patent number: 5892144
    Abstract: A biosensor (10) for measuring changes in viscosity, density and/or mass in a fluid to be examined, for example a blood coagulation sensor or immunoassay system. According to the invention, the reagents necessary for the test are contained in a support (13) which is put onto the measurement surface (18) of a piezoelectric element (8). As a blood coagulation sensor, the measurement surface (18) may according to the invention itself have a coagulation activator action or else be coated with coagulation activators.
    Type: Grant
    Filed: April 8, 1996
    Date of Patent: April 6, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Paul Meller, Norbert Madry, Carsten Schelp, Andrzej Grzegorzewski
  • Patent number: 5882924
    Abstract: The invention relates to a process for the genetic selection in microorganisms of proteins which are capable of ligand binding, in which process a protein which is capable of ligand binding is presented extracytoplasmically and the signal of the ligand binding is passed on by signal transduction to the biosynthetic machinery of the micoorganism for the purpose of expressing a detectable and/or selectable function. In addition to this, the patent discloses microorganisms which are suitable for use in this process, as well as replicons and processes for their preparation.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: March 16, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hans-Joachim Fritz, Frank Hennecke, Harald Kolmar
  • Patent number: 5883256
    Abstract: A process for removing aromatic heterocyclic compounds from a product-containing solution, in particular a protein solution, by bringing the solution into contact with a support material. The process is preferably carried out following a virus inactivation with acridine or acridine derivatives and makes it possible to remove these virus-inactivating agents from the solution without there being any significant product losses or changes in the biological activity of the solution.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: March 16, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Eckhard Schuler, Karl-Heinz Wenz
  • Patent number: 5877158
    Abstract: Substrate-spacer-prodrug compounds (pro-prodrugs) suited for site specific delivery of drugs, a process of preparing them and their use are described.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: March 2, 1999
    Assignees: Behringwerke Aktiengesellschaft, Laboratoires Hoechst S/A
    Inventors: Klaus Bosslet, Jorg Czech, Dieter Hoffmann, Fran.cedilla.ois Tillequin, Jean-Claude Florent, Michel Azoulay, Claude Monneret, Jean-Claude Jacquesy, Jean-Pierre Gesson, Michel Koch
  • Patent number: 5858723
    Abstract: Polypeptides are disclosed that are useful for diagnosing seminoma. The polypeptides have a sequence that corresponds to the amino acid sequence of the human endogenous retrovirus K10 (HERV-K10). Also disclosed are recombinant human endogenous retrovirus K10 (HERV-K10) env and gag polypeptides that are synthesized using genetic engineering techniques, constructs and processes for producing the recombinant polypeptides, and an assay for detecting the presence of antibodies specific for HERV-K10 env and/or gag polypeptides in human bodily fluids.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: January 12, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Nikolaus Mueller-Lantzsch, Marlies Sauter
  • Patent number: 5859185
    Abstract: The invention relates to peptides for the immunochemical determination of human cytomegalovirus (HCMV)-specific antibodies and HCMV antigens, and to agents suitable for this method and to the use thereof.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: January 12, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Werner Stuber, Leszek Wieczorek, Robert Ziegelmaier
  • Patent number: 5849799
    Abstract: Methods are disclosed for treatment of hyperreactive inflammatory diseases of humans and animals comprising administering a pharmaceutically effective amount of deoxyspergualin to a human or an animal.
    Type: Grant
    Filed: March 20, 1995
    Date of Patent: December 15, 1998
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Jurgen Lindner, Gerhard Dickneite, Hans-Ulrich Schorlemmer, Klaus Bosslet
  • Patent number: 5830638
    Abstract: A permanent cell line PH2, and a process for replication of rabies viruses which have a cytopathic effect (CPE) is claimed. The process comprises: infecting the PH2 cell line with the virus to be replicated; incubating the cells; and isolating and purifying virus particles after they have reached a sufficiently high titer.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: November 3, 1998
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Dieter Bernhardt, Albrecht Groner
  • Patent number: 5804430
    Abstract: A bovine ovary cell line (FROv), a process for its preparation, and its use for replicating viruses, are described.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: September 8, 1998
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Dieter Bernhardt
  • Patent number: 5798205
    Abstract: A novel HIV type O immunodeficiency virus is disclosed which has the designation MVP-2901/94 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 95012601. The characteristic antigens which can be obtained from the virus and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the partial DNA and amino acid sequences of the virus.
    Type: Grant
    Filed: February 16, 1996
    Date of Patent: August 25, 1998
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hans-Peter Hauser, Stefan Knapp, Stefan Brust, Lutz G. Gurtler, Josef Eberle, Lazare Kaptue, Leopold Achenqui Zekeng